Imatinib plus Peginterferon Alfa-2a in Chronic Myeloid Leukemia
Top Cited Papers
- 23 December 2010
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 363 (26), 2511-2521
- https://doi.org/10.1056/nejmoa1004095
Abstract
Imatinib (400 mg daily) is considered the best initial therapy for patients with newly diagnosed chronic myeloid leukemia (CML) in the chronic phase. However, only a minority of patients treated with imatinib have a complete molecular remission.Keywords
This publication has 29 references indexed in Scilit:
- TGF-β–FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemiaNature, 2010
- Results of Dasatinib Therapy in Patients With Early Chronic-Phase Chronic Myeloid LeukemiaJournal of Clinical Oncology, 2010
- Nilotinib As Front-Line Treatment for Patients With Chronic Myeloid Leukemia in Early Chronic PhaseJournal of Clinical Oncology, 2010
- IFNα activates dormant haematopoietic stem cells in vivoNature, 2009
- Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapiesLeukemia, 2007
- Phase II, randomized, multicenter, comparative study of peginterferon–α–2a (40 kD) (Pegasys®)versusinterferon α-2a (Roferon®-A) in patients with treatment-naïve, chronic-phase chronic myelogenous leukemiaLeukemia & Lymphoma, 2007
- Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid LeukemiaNew England Journal of Medicine, 2006
- Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 yearsBlood, 2006
- Pegylated recombinant interferon alpha-2b vs recombinant interferon alpha-2b for the initial treatment of chronic-phase chronic myelogenous leukemia: a phase III studyLeukemia, 2003
- Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid LeukemiaNew England Journal of Medicine, 2003